VANCOUVER, British Columbia–(HSMN NewsFeed)–Medifocus Inc. (OTC:MDFZF.PK and TSXV:MFS) is pleased to announce that it has received from the Food and Drug Administration (FDA) an Investigational Device Exemption (IDE) approval to initiate a pivotal Phase …
Devices, Oncology, FDA
Medifocus, Microfocus, hyperthermia therapy, breast cancer

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Medifocus, Inc. Announces That It Has Received Approval to Initiate Its Pivotal Phase III Clinical Trial for Treatment of Breast Cancer from the Food and Drug Administration (FDA), Investigational Device Exemption (IDE) Application”
Leave a Comment